Showing results (571-580 of 600) with videos related to
Sort By:
Pageof 60
Arthritis & Rheumatology (Hoboken, N.J.)|February 25, 2015
Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic ImplicationsYuji Yoshida, Atsushi Ogata, Sujin Kang, et al.Arquivos Brasileiros De Cardiologia|July 21, 2021
Association of Body Composition with Arterial Stiffness in Long-lived PeopleFlávia Veríssimo Melo E Silva, Franciellen Bruschi Almonfrey, Cinthia Medice Nishide de Freitas, et al.Cell Host & Microbe|May 22, 2018
A Sialylated Voltage-Dependent Ca2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian CellsYoichiro Fujioka, Shinya Nishide, Toyoyuki Ose, et al.Nature Communications|April 24, 2025
Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitisMasayuki Nishide, Kei Nishimura, Hiroaki Matsushita, et al.Nature Communications|October 13, 2016
Polarization of M2 macrophages requires Lamtor1 that integrates cytokine and amino-acid signalsTetsuya Kimura, Shigeyuki Nada, Noriko Takegahara, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2015
mTOR Complex Signaling through the SEMA4A-Plexin B2 Axis Is Required for Optimal Activation and Differentiation of CD8+ T CellsDaisuke Ito, Satoshi Nojima, Masayuki Nishide, et al.Annals of the Rheumatic Diseases|April 19, 2017
Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitisMasayuki Nishide, Satoshi Nojima, Daisuke Ito, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2018
Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EBYoshitomo Hayama, Tetsuya Kimura, Yoshito Takeda, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 4, 2017
Lamtor1 Is Critically Required for CD4+ T Cell Proliferation and Regulatory T Cell Suppressive FunctionTakashi Hosokawa, Tetsuya Kimura, Shigeyuki Nada, et al.Internal Medicine (Tokyo, Japan)|July 31, 2022
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic CancerKaori Hino, Tomohiro Nishina, Yuuki Numata, et al.Pageof 60